

# Expression of a Functional zipFv Antibody Fragment and Its Fusions with Alkaline Phosphatase in the Cytoplasm of an *Escherichia coli*

Byung-ung Hur<sup>1</sup>, Hyo-jung Choi<sup>1</sup>, Jae-bong Yoon<sup>1</sup> and Sang-hoon Cha<sup>2,3\*</sup>

<sup>1</sup>Division of Molecular & Medical Biotechnology, College of Biomedical Science, <sup>2</sup>IG Therapy Co., <sup>3</sup>Department of System Immunology, College of Biomedical Science, Kangwon National University, Chuncheon 200-701, Korea

**Background:** Expression of recombinant antibodies and their derivatives fused with other functional molecules such as alkaline phosphatase in *Escherichia coli* is important in the development of molecular diagnostic reagents for biomedical research. **Methods:** We investigated the possibility of applying a well-known Fos-Jun zipper to dimerize V<sub>H</sub> and V<sub>L</sub> fragments originated from the Fab clone (SP 112) that recognizes pyruvate dehydrogenase complex-E2 (PDC-E2), and demonstrated that the functional zipFv-112 and its alkaline phosphatase fusion molecules (zipFv-AP) can be produced in the cytoplasm of Origami(DE3) *trxB gor* mutant *E. coli* strain. **Results:** The zipFv-AP fusion molecules exhibited higher antigen-binding signals than the zipFv up to a 10-fold under the same experimental conditions. However, conformation of the zipFv-AP seemed to be influenced by the location of an AP domain at the C-terminus of V<sub>H</sub> or V<sub>L</sub> domain [zipFv-112(H-AP) or zipFv-112(L-AP)], and inclusion of an AraC DNA binding domain at the C-terminus of V<sub>H</sub> of the zipFv-112(L-AP), termed zipFv-112(H-AD/L-AP), was also beneficial. Cytoplasmic co-expression of disulfide-binding isomerase C (DsbC) helped proper folding of the zipFv-112(H-AD/L-AP) but not significantly. **Conclusion:** We believe that our zipFv constructs may serve as an excellent antibody format bi-functional antibody fragments that can be produced stably in the cytoplasm of *E. coli*.

[Immune Network 2010;10(2):35-45]

## INTRODUCTION

Recombinant antibodies composed of antigen-binding fragments of whole antibodies such as Fv, scFv or Fab have been acknowledged to have many applications in biological research. They also offer several advantages including the production of functional forms in bacteria and easy genetic manipulation to confer desired features to the antigen-binding fragments (1,2). The smallest functional unit of antibodies required for proper antigen binding is an Fv fragment, a heterodimer of the heavy chain variable domain (V<sub>H</sub>) and the light chain variable domain (V<sub>L</sub>). Unlike whole IgG or Fab molecules, however, the dissociation constant between the V<sub>H</sub> and V<sub>L</sub> domains of an Fv fragment ranges only from 10<sup>-5</sup>~10<sup>-8</sup> M, which is not sufficient to keep the domains associated with each other since there are no interchain disulfide interactions (3-5).

As an alternative, V<sub>H</sub> and V<sub>L</sub> domains are connected *via* a short peptide linker so that stable Fv fragments can be produced as a single polypeptide in *Escherichia coli*. Such single-chain variable fragments (scFv) are generally known to retain antigen-binding specificity and affinity of the parent antibody (6-9). The scFv format of an antibody molecule has a distinctive advantage over its Fab counterpart in that high yield can be obtained in *E. coli* because of a single polypeptide structure in nature. In some cases, however, scFv fragments are unstable and have a much lower affinity against

Received on March 2, 2010. Revised on March 15, 2010. Accepted on March 19, 2010.

© This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

\*Corresponding Author. Tel: 82-33-250-6485; Fax: 82-33-253-6485; E-mail: chash@kangwon.ac.kr

Keywords: Fv, Leucine zipper, Recombinant antibody, Alkaline phosphatase, DsbC

the antigens than that of Fab or whole Ig counterpart, especially when they are fused to toxins for constructing recombinant immunotoxins, probably due to the interference of a peptide linker with antigen binding or in sufficient stabilization of the Fv molecules (10,11). To circumvent this drawback, it had been attempted to utilize a disulfide-stabilized Fv (dsFv) fragment that can be generated by introducing interchain disulfide bonds artificially at the framework regions of V<sub>H</sub> and V<sub>L</sub> domains (12,13). A dsFv fragment is found to be considerably more stable and shows better antigen-binding capacity than the corresponding scFv counterpart, suggesting that dsFv format is more useful than scFv as therapeutic and diagnostic reagents (14,15). Unfortunately, generation of a dsFv is not trivial because appropriate amino residues in conserved framework regions have to be identified for the disulfide bridge by molecular modeling technology, followed by cumbersome point-directed mutagenesis.

Another problem in producing functional antibody fragments, even scFv, in *E. coli* is that a reduced state of the *E. coli* cytoplasm acts strongly against the formation of disulfide bonds in proteins (16). Therefore, antibody fragments must be secreted to the periplasmic space, but it frequently leads to a low yield of soluble antibody fragments primarily due to the aggregation and degradation of the fragments in the periplasm, inefficient translocation through the cytoplasmic membrane, and lysis of host cells in many cases (17-19). Expression of antibody fragments in the cytoplasm of *E. coli* may alleviate cellular toxicity if the mutant *txxB E. coli* strain that has much oxidizing cytoplasmic environment were utilized so that the formation of disulfide bonds of polypeptides in the cytoplasm is allowed (20). For examples, high yield of functional scFv fragments from the anti-progesterone antibody, DB3, has been obtained by cytoplasmic expression of the antibody fragments using *E. coli* ADA494 strain (*txxB* mutant) (21,22), and soluble Fab antibody fragments have also been successfully produced in the cytoplasm of *E. coli txxB gor* mutant (23,24).

In this study, we accessed the possibility of producing a novel functional Fv fragment, named zipFv, by linking V<sub>H</sub> and V<sub>L</sub> fragments *via* Fos/Jun leucine zipper and its fusion polypeptides with alkaline phosphatase (AP), named zipFv-AP, and demonstrated that the functional zipFv and the zipFv-AP antibody fragments can be expressed in the cytoplasm of *E. coli txxB gor* mutant using the V<sub>H</sub> and the V<sub>L</sub> domains from SP112, the human Fab clone specific for pyruvate dehydrogenase complex-E2 (PDC-E2), as a model system.

## MATERIALS AND METHODS


### Bacterial strains and oligonucleotides

*Escherichia coli* strain ElectroTen Blue ( $\Delta(mcrA)183 \Delta(mcrCB-hsdSMR-mrr)173 \text{ endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Kan}^R$  [F' *proAB lacIqZ* $\Delta$ M15 Tn10 (Tet<sup>R</sup>)] (Stratagene, USA) was used as the bacterial host for the preparation of recombinant vectors and DNA cloning, and Origami(DE3) ( $\Delta(ara-leu)7697 \Delta lacX74 \Delta phoA PvuII phoR araD139 aphC galE galK rpsL$  F'[*lac*<sup>+</sup> *lacI*<sup>f</sup> *pro*] (DE3) *gor522::Tn10 txxB* (Kan<sup>R</sup>, Str<sup>R</sup>, Tet<sup>R</sup>)) (Novagen, USA) for the expression of recombinant antibody fragments. All oligonucleotides used in this study were synthesized from Bioneer Co. (South Korea).

### DNA cloning procedure

All DNA cloning experiments were carried out according to the standard procedures (25), and *Ex-Taq* polymerase and *Pfu* DNA polymerase (Takara, Japan) were successfully used for the polymerase chain reactions (PCR). The pCzFv, pCzFvHAP and pCzFvLAP vectors were constructed previously as shown in Fig. 1 (IG Therapy, South Korea, unpublished). The V<sub>H</sub> and the V<sub>Lκ</sub> chain genes were PCR amplified from SP112 Fab clone (26) at the condition of 35 cycles of 94°C 1 min, 55°C 1 min, 72°C 1 min, followed by 72°C soaking for 10 min using human Ig-specific V<sub>H</sub> and J<sub>H</sub>, or V<sub>Lκ</sub> and J<sub>κ</sub> primers synthesized according to the previous report with slight modification (V<sub>H</sub> sense: 5'-GGGGGCCAGCCG-GCCATGGCCGAGGTGCAGCTGGTGGAGTCTGG-3', J<sub>H</sub> anti-sense: 5'-GGGGGCCACATTGGCCGATGAGGAGACGGTGAC-CAKGTBCCCTTGGCCCA-3', V<sub>κ</sub> sense: V<sub>Lκ</sub> forward: 5'-GGG-GTCGACATGGAAATTGAGTTGACGACAGTCTCC-3', J<sub>κ</sub> anti-sense: 5'-GGGCCGCGATACGTTTGTATHCCASYTTGGTCCC-3'; where *Sfi* I, *Sal* I and *Sac* II recognition sites were underlined, and degeneracy is denoted as follows: H=A, C or T; S=G or C; Y=C or T; K=G or T; B=G, T or C) (27).

The V<sub>Lκ</sub> gene fragment of SP112 was recovered from 1.2% agarose gel, treated with *Sal* I and *Sac* II (Takara), and cloned into pCzFv, pCzFvHAP and pCzFvLAP at a 2 : 1 molar ratio using T4 DNA ligase (Takara) at 16°C overnight. The resulting DNA ligated reactions were electroporated into ElectroTen Blue competent cells using Gene Pulser (Biorad, USA) at 2.5 kV, 25 μF and 400 Ω, and the transformed cells were recovered by growing them in SOC medium for 1 h at 37°C. Then, the cell suspensions were spread onto 2 × YT plates containing 50 μg/ml ampicillin (2 × YT/amp). *E. coli* colonies carrying pCzFv, pCzFvHAP or pCzFvLAP vectors with correct V<sub>Lκ</sub>



**Figure 1.** Schematic diagram depicting the cytoplasmic zipFv expression vectors used in this study.

insert were identified by cutting the miniprep plasmid with *Sal* I and *Sac* II, followed by 1.2% agarose gel electrophoresis. Thereafter, the  $V_H$  gene obtained from SP112 was treated with *Sfi* I (Takara), and subsequently cloned into the pCzFv, pCzFvHAP, and pCzFvLAP vectors containing  $V_L$  inserts. The resulting pCzFv, pCzFvHAP and pCzFvLAP vectors having both  $V_H$  and  $V_L$  genes of SP112 were named as pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112, respectively, and electroporated into Origami(DE3) cells.

The gene encoding a DNA binding domain of AraC (amino acid residues 168~291) ( $Ara_{DNA}$ ) (28,29) was obtained by PCR amplification from the pBAD/gIII vector (Invitrogen, USA) using PCR primers (sense: 5'-GGGACTAGTAACGAGTCGCTCCATCCACCG-3'; antisense: 5'-GGGGTCGACACTAGTTTATGACAACTTGACGGCTAC ATCA-3', where *Spe* I recognition site was underlined). The resulting 408 bp PCR products were digested with *Spe* I restriction enzyme, and cloned into the pCzFvLAP-112 that had been treated with *Nhe* I. The ligation reaction was electroporated into ElectroTen Blue cells and finally into Origami(DE3) as above. The resulting construct was named pCzFvHADLAP-112.

For the cytoplasmic co-expression of DsbC, the full-length *E. coli* DsbC gene without signal peptide sequence was obtained from the genomic DNA of BL21(DE3) cells by PCR using following PCR primers (sense: 5'-GGGCATATGGATGA-

CGCGGCAATTCAACAA-3', antisense: 5'-GGGGGTACCTTATTACCGCTGGTCATTTTTTIG-3', *Nde* I and *Kpn* I restriction sites were underlined). The resulting PCR products were recovered from 1% agarose gel using Wizard DNA purification kit (Promega, USA). Then the DNA fragments were restricted with *Nde* I/*Kpn* I, and cloned into pCDFDuet (Novagen), resulting in the construction of pCDF-DsbC. Origami(DE3) cells were transformed with the construct, and selected with LB medium supplemented with 50  $\mu$ g/ml of spectinomycin (Sigma Co.).

### Preparation of antigens

Recombinant inner lipoyl domain of human PDC-E2 (residues 91~227) fused to glutathione S-transferase (GST) was prepared by growing *E. coli* having pGEX vector with PDC-E2 inner lipoyl domain cDNA in 200 ml of LB containing 50  $\mu$ g/ml ampicillin (LB/amp) supplemented with 1 mM isopropyl- $\beta$ -D-1-thiogalactopyranoside (IPTG) until  $OD_{600}=0.5$  at 37°C (30). The cell culture was centrifuged at 3,000 $\times g$  for 10 min, and the resulting cell pellet was resuspended in 5 ml of ice-cold phosphate-buffered saline (PBS) supplemented with 1% Triton X-100 (Sigma Co.). The cell suspension was sonicated 5 times for 5 sec each with 2 min intervals on ice in the presence of 100  $\mu$ g/ml phenylmethylsulfonyl fluoride (PMSF) (Sigma Co.), and microfuged for 5 min at 4°C to re-

move cell debris. For the purification of the protein, glutathione-agarose bead (Sigma Co.) in 2 ml PBS were mixed with the supernatant at 4°C overnight, washed with ice-cold PBS 4 times, and recombinant proteins were eluted with 5 mM reduced glutathione (Sigma Co.) in 50 mM Tris-Cl (pH 8.0). Negative control antigens were prepared as follow. Maltose binding protein (MBP) was prepared by growing *E. coli* harboring pMAL-c2 (New England Biolab, USA) using amylose-binding resin according to the manufacturer's protocol. Human recombinant IL-15 proteins were produced by using pET expression system and purified with Ni-NTA resin (IG Therapy Co., unpublished). Bovine serum albumin (BSA) was purchased from Sigma Co.

#### Production of the zipFv and the zipFv-AP fragments

Origami(DE3) cells carrying pCzFv-112, pCzFvHAP-112, pCzFvLAP-112 or pCzFvHADLAP-112 were grown on 5 ml of 2× YT/amp until OD<sub>600</sub>≈approximately 0.5. Then IPTG was added into the culture at 0.1 mM final concentration, and production of the zipFv molecules was induced at 27°C for 16 h. The cells were harvested by centrifugation (4,000 rpm for 10 min) and resuspended in 2 ml of cold PBS containing 100 μg/ml of PMSF. The cell suspension was sonicated 5 times on ice, and microfuged for 5 min at 4°C to obtain cytoplasmic extract. The resulting cytoplasmic extracts were used in the enzyme-linked immunosorbent assay (ELISA). For the co-expression of DsbC and the zipFv-AP fusion molecules, electro-competent cells were prepared with Origami(DE3) cells housing pCDF-DsbC, and pCzFvHADLAP-112 was introduced into the cells by electroporation as described previously. The cells having both pCDF-DsbC and pCzFvHADLAP-112 were selected by growing them in 2× YT/amp medium supplemented with 50 μg/ml of spectinomycin.

#### ELISA

Maxisorp 96-well plates (Nunc, Denmark) were coated with 50 μl of 10 μg/ml PDC-E2, recombinant human IL-15, MBP, or BSA in coating buffer (0.1 M NaHCO<sub>3</sub>, pH 9.6) at 4°C overnight and blocked with 3% powdered milk in PBS (MPBS) for 2 h at room temperature. Then, serial dilutions of the cytoplasmic extracts (50 μl) were added into each of the micro-wells, and incubated for 2 h at 27°C. The plates were washed four times with PBS containing 0.05% Tween 20 (PBST), and mouse anti-myc tag monoclonal antibody (mAb) (IG Therapy, Co.) followed by goat anti-mouse IgG-horse radish peroxidase (HRPO) conjugated (Sigma Co.) was added and in-

cubated for 1 h at 27°C, respectively. The signal was visualized by adding 50 μl of 3,3',5,5'-tetramethyl benzidine (TMB) substrate (Sigma Co.), and the enzymatic reaction was stopped by adding an equal volume of 1 N HCl into each well. Finally, absorbance at 450 nm was measured using ELISA reader (Biorad). In order to determine the alkaline phosphatase activity (AP) of the zipFv-AP fusions bound to antigens, 50 μl of p-nitrophenyl phosphate (pNPP) substrate (Sigma Co.) were directly added into each well instead of using anti-myc tag mAb. The enzymatic reaction was stopped by adding 3 N NaOH into each well, and absorbance at 405 nm was measured using ELISA reader.

#### Western blot

Origami(DE3) cells carrying pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112 were grown in 2 ml of 2× YT/amp medium at 37°C until OD<sub>600</sub> reached approximately 0.5, and the expression of the zipFv and its AP fusion proteins was induced as above. The cells were harvested by microfugation and resuspended with SDS sample buffer with or without β-2-mercaptoethanol, and total cellular proteins were separated with 12% SDS-PAGE (25). The proteins were transferred to nitrocellulose membrane (Amersham Pharmacia, Sweden), and the membrane was blocked with MPBS. After washing the membrane three times with PBST, anti-myc tag mAb followed by incubation with goat anti-mouse IgG-alkaline phosphatase (AP) conjugated (Sigma Co.), or nitro blue tetrazolium chloride (NBT)/5-bromo-4-chloro-3-indolyl phosphate (BCIP) substrate (Sigma Co.) directly was used to detect the presence of the zipFv or its AP activity in total *E. coli* lysate. The bands on the blot were analyzed with densitometer (Biorad).

## RESULTS

#### Construction of zipFv expression vectors

It is well accepted that bacterially expressed antibody fragments (Fv, scFv or Fab) provide a simple and cost-effective alternative to the traditional production of diagnostic mAbs by animal cell tissue culture, and numerous recombinant antibody fragments have been successfully produced through periplasmic expression using *E. coli*. Although scFv format is advantageous in prokaryotic expression because of its single polypeptide structure, disulfide-stabilized Fv (dsFv) had also been recognized to be more useful than scFv as therapeutic and diagnostic agent through its superior stabilization

(14). SP112, a human Fab binds to PDC-E2, was chosen in this study because it is available in our laboratory at hand and a scFv version of SP112 does not show any significant antigen-binding reactivity to PDC-E2 (data not shown).

To evaluate whether heterodimerization of  $V_H$  and  $V_L$  of SP112 *via* Fos (40 amino acid residues in size)/Jun (40 amino acid residues in size) leucine zipper could retain the antigen-binding reactivity, a new Fv expression vector, pCzFv, was constructed using the pET22b expression vector as a backbone (Fig. 1). The Fos : Jun leucine zippers were used to link  $V_H$  and  $V_L$  fragments since they preferentially form heterodimers (Fos : Jun) at least 1,000 times over homodimers (Fos : Fos or Jun : Jun) due to greater thermodynamic stability (31), and the same amphiphilic helix leucine zipper had already been successfully used in the generation of dimeric and bispecific scFv fragments (2).

The bicistronic expression of  $V_H$ -Fos-myc and  $V_L$ -Jun-S1 gene fragments driven by a single p7 promoter ensures the equal transcription of the fragments, and partial mouse IgG<sub>3</sub> hinge fragments (10 amino acid residues in size) are introduced between the  $V_H$  and Fos domains as well as between the  $V_L$  and Jun domains to confer structural flexibility. Two cysteine residues are also added at the flanking region of each Fos and Jun segment, respectively, so that two inter-chain disulfide bonds could be formed in the zipper region to reinforce the binding of Fos/Jun dimer (2). In addition, myc tag and S1 tag are placed at the end of Fos or Jun, respectively, to facilitate the detection of each antibody fragments.


As similar to a scFv-AP fusion produced in the periplasm of bacteria (32), fusion of AP to the zipFv might be advantageous in that binding of the antibody fragments to antigen can be analyzed in an ELISA or Western blot without use of additional enzyme-conjugated antibodies. Thereby, the pCzFv vector was further modified to pCzFvHAP or pCzFvLAP vector by linking leaderless *phoA* gene (1,470 bp in length) encoding alkaline phosphatase (AP) (46.5 kDa in size) at the 3' end of either the  $V_H$ -Fos-myc or the  $V_L$ -Jun-S1 gene fragment, respectively, to produce the zipFv-AP fusion proteins [zipFv-112(H-AP) or zipFv-112(L-AP)]. Finally, the  $V_H$  and the  $V_L$  genes of SP112 were cloned into the pCzFv, pCzFvHAP and pCzFvLAP vectors, and the resulting vector constructs, named as pCzFv-112, pCzFvHAP-112 and pCzFvLAP-112, respectively, were electroporated into Origami(DE3) *txB gor* mutant *E. coli* cells.

### Expression and characterization of the zipFv and the zipFv-AP fusion proteins


The Origami(DE3) *txB gor* cells carrying pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112 were grown in 2× YT/amp medium, and the recombinant antibody fragments were expressed by adding 0.1 mM IPTG at 27°C for 16 h. The zipFv and the zipFv-AP fusion proteins produced by each of the host cells were named as zipFv-112, zipFv-112(H-AP) or zipFv-112(L-AP), respectively. The optimal induction condition had been pre-determined using various concentrations of IPTG (0~1 mM), temperature (27°C or 37°C) and induction time (2~16 h). Growing cells at 27°C for 16 h produced at least 1~3 times more functional zipFv and zipFv-AP fusion fragments than at 37°C for 4 h, and 0.1 mM final concentration of IPTG gave the highest yield of recombinant antibody fragments (data not shown). It was noteworthy that no host cell lysis was observed during IPTG induction of the zipFv or zipFv-AP fusion proteins whereas over-expression of SP112 in the periplasm of *E. coli* caused host cell lysis (data not shown).

To determine the antigen-binding specificity of the antibody fragments present in the cytoplasmic extracts of the host cells, ELISA was performed using microtiter plates coated with recombinant PDC-E2, recombinant human IL-15, MBP or BSA. Anti-myc tag mAb was used for detecting the antibody fragments bound to antigens. As shown in Fig. 2, the zipFv-112 and its AP fusions, the zipFv-112(H-AP) and the zipFv-112(L-AP), specifically reacted to PDC-E2 only, but not to any other negative control antigens, demonstrating that the recombinant antibody fragments of the zipFv and the zipFv-AP formats retained the antigen-binding specificity of SP112, even if they were produced in the cytoplasm of the host cells. This also implied that the proper disulfide bonds were formed between the  $V_H$ -Fos-myc fragment and the  $V_L$ -Jun-S1 fragment in the cytoplasm of the *txB gor* mutant *E. coli*.

Since Fig. 2 showed that the zipFv-112 fragment exhibited the weakest antigen-binding signal among the three antibody fragments, yield of the functional zipFv-112, the zipFv-112(H-AP) and the zipFv-112(L-AP) in the cytoplasmic extracts were compared by ELISA (Fig. 3). The cytoplasmic extracts from the cells that grown at the exactly same experimental conditions were prepared and serial dilutions were made in MPBS. Mouse anti-myc tag mAb followed by goat anti-mouse IgG-HRP conjugated was used to detect the  $V_H$ -Fos-myc fragments of the zipFv-112 and the zipFv-112(L-AP) or the  $V_H$ -Fos-myc-AP fragments of the zipFv-112(H-AP) that bound




**Figure 2.** ELISA to prove antigen-binding specificity of zipFv-112 and its fusions with alkaline phosphatase produced in the cytoplasm of Origami(DE3) cells. Origami(DE3) cells transformed with pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112 were grown in the presence of 0.1 mM IPTG, and the presence of PDC-E2-specific zipFv antibody fragments (zipFv-112, zipFv-112(H-AP) or zipFv-112(L-AP)) in the cytoplasmic extracts was determined by ELISA. Mouse anti-myc tag mAb was used for a primary antibody as described under Materials and Methods. MBP, IL-15 and BSA were used as negative control antigens, and TMB substrate was used to visualize signals. Data represent the average of three experiments  $\pm$  standard deviation.



**Figure 3.** Comparison of antigen-binding reactivity of the zipFv-112 and its fusions with alkaline phosphatase produced in the cytoplasm of Origami(DE3) cells by ELISA using anti-myc mAb for detecting the  $V_H$ -Fos-myc fragments. Origami(DE3) cells producing zipFv-112, zipFv-112(H-AP) and zipFv-112(L-AP) were grown in the presence of 0.1 mM IPTG, and the presence of PDC-E2-specific zipFv-AP antibody fragments in the serial dilutions of the cytoplasmic extracts was determined by ELISA using anti-myc mAb followed by goat anti-mouse IgG-HRPO conjugated for detecting the  $V_H$ -Fos-myc or the  $V_H$ -Fos-myc-AP fusions as described under Materials and Methods. TMB substrate was used to visualize signals. Data represent the average of three experiments  $\pm$  standard deviation.

to PDC-E2. The results revealed that the zipFv-112(H-AP) showed about 4 times higher binding signal to PDC-E2 than




**Figure 4.** Comparison of antigen-binding reactivity of anti-PDC-E2 zipFv fused with alkaline phosphatase by ELISA. Origami(DE3) cells producing the zipFv-112(H-AP) and the zipFv-112(L-AP) were grown in the presence of 0.1 mM IPTG, and the presence of PDC-E2-specific zipFv-AP antibody fragments in the serial dilutions of the cytoplasmic extracts was determined by ELISA using AP substrate, pNPP, for detecting AP activity of the  $V_H$ -Fos-myc-AP or the  $V_L$ -Jun-AP fusions as described under Materials and Methods. MBP was used as a negative control antigen. Data represent the average of three experiments  $\pm$  standard deviation.

that of the zipFv-112(L-AP) and 10 times higher than that of the zipFv-112, implying that the AP fusion at the C-terminus of the  $V_H$ -Fos-myc of the zipFv increases yield of the functional antibody fragments uppermost. To confirm this finding, experiments were performed as same as Fig. 3 using the same cytoplasmic extracts containing the zipFv-112(H-AP) or the zipFv-112(L-AP), except that AP substrate (pNPP) instead of anti-myc tag mAb was directly applied to visualize ELISA signals (Fig. 4). Unexpectedly, the data indicated that PDC-E2-binding signal of the zipFv-112(H-AP) was about 5-fold lower than that of the zipFv-112(L-AP). It implies that that an AP domain of the  $V_L$ -Jun-S1 would block the myc-tag epitope of the  $V_H$ -Fos-myc domain that recognized by anti-myc tag mAb in the zipFv-112(L-AP).

#### Western blot analysis to determine the expression level of the $V_H$ and the $V_L$ fusion molecules

To understand these contradictory results, cell lysates of Origami(DE3) *trxB gor* cells housing pCzFv-112, pCzFvHAP-112 or pCzFvLAP-112 were prepared, and the same concentration of total proteins were analyzed by western blot (Fig. 5A). Mouse anti-myc tag mAb followed by anti-mouse IgG-AP conjugated was used to determine expression level of the  $V_H$ -Fos-myc of the zipFv-112 or the zipFv-112(L-AP), and the



**Figure 5.** Western blot showing the expression of the  $V_H$ -Fos-myc, the  $V_H$ -Fos-myc-AP or the  $V_L$ -Jun-AP fragments of the zipFv-112, the zipFv-112(H-AP) and the zipFv-112(L-AP). Origami(DE3) cells expressing the zipFv-112, the zipFv-112(H-AP) and the zipFv-112(L-AP) were grown in  $2 \times$  YT/amp medium supplemented with 0.1 mM IPTG, and total proteins in the cell lysates were separated by using 12% SDS-PAGE at reducing (A, lane 1 on B) and non-reducing (Lane 2 on B) condition. Western blot was performed using either mouse anti-myc tag mAb followed by goat anti-mouse IgG-AP conjugated or NBT/BCIP substrate directly as described under Materials and Methods to detect the presence of the  $V_H$ -Fos-myc and the  $V_H$ -Fos-myc-AP, or AP activity of the  $V_H$ -Fos-myc-AP and the  $V_L$ -Jun-AP polypeptides, respectively.

$V_H$ -Fos-myc-AP fragment of the zipFv-112(H-AP) in the cell lysates. In addition, the AP activity of the  $V_H$ -Fos-myc-AP of the zipFv-112(H-AP) and the  $V_L$ -Jun-S1-AP of the zipFv-112(L-AP) was also measured by applying NBT/BCIP substrate directly to the blot. The densitometric analysis of the blot revealed that the  $V_H$ -Fos-myc (21 kDa) of the zipFv-112 was expressed about 5-fold higher than the  $V_H$ -Fos-myc-AP (67.5 kDa) of the zipFv-112(H-AP) and 4-fold higher than the  $V_H$ -Fos-myc of the zipFv-112(L-AP), even though the zipFv-112 showed the weakest antigen-binding signal in ELISA as shown in Fig. 3. To resolve this contradiction we carried out

western blot analysis of the cell lysate expressing the zipFv-112 at reducing and non-reducing conditions of 12% SDS-PAGE using anti-myc mAb, and the results revealed that only 7% of total  $V_H$ -Fos-myc fragments in the cytoplasm of Origami(DE3) cells formed the functional zipFv molecules according to densitometry analysis, indicating that majority of the  $V_H$ -Fos-myc and the  $V_L$ -Jun-S1 fragments were not properly dimerized each other in the cytoplasm of Origami(DE3) cells (Fig. 5B). On the other hand, the fusion of an AP moiety at the C-terminus of either the  $V_H$ -Fos-myc or the  $V_L$ -Jun-S1 resulted in lower expression of the  $V_H$ -Fos-myc of both zipFv-112(H-AP) and zipFv-112(L-AP). Difference in expression level between the  $V_H$ -Fos-myc-AP of the zipFv-112(H-AP) and the  $V_H$ -Fos-myc of the zipFv-112(L-AP) was meager, although the zipFv-112(H-AP) showed a 4-fold higher binding signal to PDC-E2 than the zipFv-112(L-AP) as shown in Fig. 3.


Interestingly, blot data by using AP substrate (NBT/BCIP) directly showed that the  $V_L$ -Jun-S1-AP of the zipFv-112(L-AP) seemed to be produced 50-fold higher than the  $V_H$ -Fos-myc-AP of the zipFv-112(H-AP) in the cytoplasm of the cells. This may explain a 5-fold higher antigen-binding signal of the zipFv-112(L-AP) than that of the zipFv-112(H-AP) as shown in Fig. 4. However, additional SDS-PAGE analysis followed by Coomassie blue staining revealed that the higher AP activity of the  $V_L$ -Jun-S1-AP of the zipFv-112(L-AP) didn't come from the higher expression level of the fragment than the  $V_H$ -Fos-myc-AP of the zipFv-112(H-AP) (data not shown). Taken together, the data imply that the positioning of the AP moiety at the C-terminus of the  $V_H$ -Fos-myc somehow hinders AP activity. Unfortunately, we were not able to present western blot data showing  $V_L$ -Jun-S1 and  $V_L$ -Jun-S1-AP expression level because commercial anti-S1 tag mAb produced too much background on the blot. Our unpublished observation indicated that  $V_H$  domain usually has a higher tendency to aggregate each other compared to  $V_L$  domain when it is expressed in *E. coli* probably due to the hydrophobic residues exposed outward. Therefore, we assume that presence of AP seemed to reduce this self-aggregation probably by concealing hydrophobic residues in the variable regions (33), resulting in the increase of functional zipFv-AP molecules compared with a zipFv format.

### Effect of an irrelevant fusion moiety at the C-terminus of the V<sub>H</sub>-Fos-myc on the functionality of the zipFv-112(L-AP) construct

We further investigated to see whether incorporation of an irrelevant protein, such as DNA-binding domain of AraC (AraC<sub>DNA</sub>), at the C-terminus of the V<sub>H</sub>-Fos-myc of the zipFv-112(L-AP) might improve detection of the antigen-binding zipFv-112(L-AP) by anti-myc tag mAb while keeping its high AP activity. AraC<sub>DNA</sub> was chosen because the gene fragment encoding the protein with appropriate restriction enzyme recognition sites was readily available in our laboratory, and it had been acknowledged that the domain could be produced in soluble form in the cytoplasm of *E. coli* (34). The gene fragment of the AraC<sub>DNA</sub> was cloned at the 3' end of myc tag of the pCzFvLAP-112 to construct the pCzFvHADLAP as shown in Fig. 1, and the resulting zipFv-112(H-AD/L-AP) fragments were produced in Origami(DE3) cells. The antigen-binding intensity of the zipFv-112(L-AP) and the zipFv-112(H-AP) was compared by ELISA using anti-myc tag mAb as Fig. 3 (Fig. 6). The ELISA results showed that the fusion of AraC<sub>DNA</sub> domain at the C-terminus of the V<sub>H</sub>-Fos-myc of the zipFv-112(L-AP) restored the antigen-binding signal of the zipFv-112(H-AD/L-AP) to the same degree as that of the zipFv-112(H-AP), indicating that the presence of a irrelevant protein moiety at the C-terminus of the V<sub>H</sub>-Fos-myc exposes myc epitope properly. In terms of AP activity, the zipFv-112(H-AD/L-AP) showed the similar degree of antigen-binding intensity as the zipFv-112(L-AP) when AP substrate was used directly in ELISA (data not shown).

### Effect of DsbC on the functional expression of the zipFv-AP fragments

Co-expression of chaperone proteins such as the Skp chaperone protein with antibody fragments had been reported to reduce toxicity and to enhance the proper folding of scFv or Fab fragments expressed in *E. coli* (35), and Levy *et al* demonstrated that co-expression of Skp or DsbC chaperone protein increased the cytoplasmic production of functional Fab fragments up to 5-6-fold (23). Additionally, DsbC co-expression increases the yield of tissue plasminogen activator (tPA) in the cytoplasm of *E. coli* by more than 20-fold (36). Since only minor fraction (<10%) of total V<sub>H</sub>-Fos-myc dimerized with the V<sub>L</sub>-Jun-S1 fragments to become functional zipFv or zipFv-AP, we assumed that the same strategy may work for the improved expression of the functional zipFv fragments.




**Figure 6.** Comparison of antigen-binding reactivity of the zipFv-112(L-AP) and the zipFv-112(H-AP) produced in the cytoplasm of Origami(DE3) cells by ELISA using anti-myc mAb for detecting signals. Origami(DE3) cells producing zipFv-112(L-AP) and zipFv-112(H-AP) were grown in the presence of 0.1 mM IPTG, and presence of the functional zipFv-AP with PDC-E2 binding reactivity in the serial dilutions of the cytoplasmic extracts was determined by ELISA using mouse anti-myc mAb followed by goat anti-mouse IgG-HRPO conjugated for detecting the V<sub>H</sub>-Fos-myc or the V<sub>H</sub>-Fos-myc-AP fragments. Data represent the average of three experiments  $\pm$  standard deviation.

To test whether co-expression of DsbC further improves a production of the functional zipFv-112(H-AD/L-AP), DsbC gene without signal peptide was cloned into pCDFDuet vector. The resulting pCDF-DsbC construct was electroporated into Origami(DE3) cells, and the cytoplasmic expression of a leaderless version of DsbC (217 amino acids, approximately 24 kDa in size) upon IPTG induction was confirmed by 12% SDS-PAGE (data not shown). Electrocompetent Origami(DE3) cells housing pCDF-DsbC were transformed with pCzFvHADLAP-112, and ELISA was performed to compare PDC-E2-binding intensity of the zipFv-112(H-AD/L-AP) expressed with or without DsbC (Fig. 7). The data revealed that the zipFv-112(H-AD/L-AP) with DsbC gave about 1.5-fold higher ELISA signal to the antigen than that of zipFv-112(H-AD/L-AP) without DsbC when anti-myc tag mAb was used for detecting signals (Fig. 7A). However, no beneficial effect was observed on the V<sub>L</sub>-Jun-S1-AP stabilization since no improvement on antigen-binding signal was found (Fig. 7B), suggesting that cytoplasmic co-expression of DsbC does not improve functional dimerization of the V<sub>H</sub>-Fos-myc-AD and the V<sub>L</sub>-Jun-S1-AP significantly.

Considering that cytoplasmic Fab showed substantial antigen-binding reactivity even at 200-300-fold dilution (23,24), it appeared that the zipFv-AP fusions showed much weaker





**Figure 7.** Effect of DsbC on the production of functional zipFv-112(H-AD/L-AP) determined by ELISA. Origami(DE3) cells carrying pCDF-DsbC were transformed with the pCzFvHADLAP-112, and grown in the presence of 0.1 mM IPTG. Presence of the functional zipFv-112(H-AD/L-AP) that bound to PDC-E2 with or without DsbC co-expression was determined using serial dilutions of the cytoplasmic extracts. (A) Mouse anti-myc mAb followed by goat anti-mouse IgG-HRPO conjugated or (B). pNPP, AP substrate, was used to detect antigen-binding signals in ELISA. Data represent the average of three experiments  $\pm$  standard deviation.

antigen-binding intensity compared to the Fab fragments produced by cytoplasmic expression. We assume that this might come from the different experimental setups in that we prepared 1.5 ml of the cytoplasmic extracts from 3 ml culture, but Venturi *et al* used 10 ml of the cytoplasmic extracts obtained from 2 liters of culture for ELISA (24), meaning that their Fab preparation should give an 100-fold higher signal than ours. In the case of the zipFv-112(H-AD/L-AP), it gave a good antigen-binding signal at 1/32 dilution factor, and it can be inferred from the results that this construct would produce as much as 10-fold higher yield of functional cytoplasmic antibody fragments than Fab format. It is possible that high expression rate of our zipFv-AP fusions compared to Fab fragments may come from the different IPTG induction protocol for recombinant antibody production that we used 27°C 16 h, whereas cytoplasmic Fab expression was performed at 37°C 4 h. Venturi *et al* also reported that 50~250 times higher yield of Fab fragments could be obtained by cytoplasmic expression than in the periplasmic space, but we were not able to confirm this observation since we didn't have periplasmic expression module for the zipFv or the zipFv-AP fusions.

It is possible that functional zipFv fragments might form more efficiently than Fab fragments in the cytoplasm of the mutant *E. coli* because the zipFv requires four pairs of disulfides, two pairs of disulfides in the variable regions and another two pairs between Fos and Jun zipper, whereas Fab

needs five pairs in total, including one intramolecular disulfide in the C<sub>H1</sub>, one in C<sub>L</sub> kappa, and an intermolecular disulfide linking. However, comparison of the yield between the zipFv and Fab above is only circumstantial unless an identical antibody gene is expressed using the same expression module at the same experimental condition. Additionally, (His)<sub>6</sub> tag needs to be implemented to zipFv or zipFv-AP format for purification of the molecules to address the issues on the yield of the antibody molecules precisely and quantitatively.

## DISCUSSION

In this study, we demonstrated that a functional Fv fragment can be generated by dimerizing V<sub>H</sub> and V<sub>L</sub> fragments with a well-known Fos-Jun zipper, and a resulting zipFv and its derivative fused with AP (zipFv-AP) can be produced as a functional form in the cytoplasm of Origami(DE3) *trxB gor* mutant *E. coli* strain. Interestingly, fusion of AP moiety to the zipFv-112 improved formation of the functional zipFv-AP molecules in the cytoplasm of host cells regardless of its location, and also influenced the conformation of the zipFv-AP molecules depending on its location as shown by the zipFv112 (H-AP) and the zipFv-112(L-AP). Additionally, incorporation of the AraC<sub>DNA</sub> domain into the zipFv-112(L-AP) [zipFv-112(H-AD/L-AP)] improved folding of the zipFv-AP molecules. In contrast to previous reports, cytoplasmic co-expression of DsbC seemed not as quite beneficial as expected.

Currently, we are exploring the possibility of replacing the AraC<sub>DNA</sub> domain of the zipFv-112(H-AD/L-AP) with other functional proteins, for example green fluorescent protein (GFP), to make tri-functional antibody fragments. Considering that the production of recombinant antibody fragments fused with functional molecules such as AP is important in the development of molecular diagnostic reagents for biomedical research, we believe that our zipFv-AP constructs may provide an alternative antibody format for producing bi-functional antibody fragments in the cytoplasm of *E. coli* in a secure and convenient manner, and possibly for the development of diverse antibody contents for proteome analysis.

## ACKNOWLEDGEMENTS

This research was supported by the Ministry of Commerce, Industry and Energy (MOCIE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Regional Innovation.

## CONFLICTS OF INTEREST

The author have no financial conflict of interest.

## REFERENCES

1. Morino K, Katsumi H, Akahori Y, Iba Y, Shinohara M, Ukai Y, Kohara Y, Kurosawa Y: Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. *J Immunol Methods* 257;175-184, 2001
2. Pack P, Plückthun A: Miniantibodies use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in *Escherichia coli*. *Biochemistry* 31;1579-1584, 1992
3. Horne C, Klein M, Polidoulis I, Dorrington KJ: Noncovalent association of heavy and light chains of human immunoglobulins. III. Specific interactions between V<sub>H</sub> and V<sub>L</sub>. *J Immunol* 129;660-664, 1982
4. Jäger M, Plückthun A: Domain interactions in antibody Fv and scFv fragments: effects on unfolding kinetics and equilibria. *FEBS Lett* 462;307-312, 1999
5. Jäger M, Plückthun A: Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen. *J Mol Biol* 285;2005-2019, 1999
6. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Brucoleri RE, Haber E, Crea R, et al: Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc Natl Acad Sci U S A* 85;5879-5883, 1988
7. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M: Single-chain antigen-binding proteins. *Science* 242;423-426, 1988
8. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. *Nature* 339;394-397, 1989
9. Glockshuber R, Malia M, Pfitzinger I, Plückthun A: A comparison of strategies to stabilize immunoglobulin Fv-fragments. *Biochemistry* 29;1362-1367, 1990
10. Bird RE, Walker BW: Single chain antibody variable regions. *Trends Biotechnol* 9;132-137, 1991
11. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, Pastan I: Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. *J Biol Chem* 269;18327-18331, 1994
12. Jung SH, Pastan I, Lee B: Design of interchain disulfide bonds in the framework region of the Fv fragment of the monoclonal antibody B3. *Proteins* 19;35-47, 1994
13. Reiter Y, Brinkmann U, Lee B, Pastan I: Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. *Nat Biotechnol* 14;1239-1245, 1996
14. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I: Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. *Biochemistry* 33;5451-5459, 1994
15. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I: Engineering interchain disulfide bonds into conserved framework regions of Fv fragments improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. *Protein Eng* 7;697-704, 1994
16. Skerra A, Plückthun A: Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*. *Science* 240;1038-1041, 1988
17. Krebber A, Burmester J, Plückthun A: Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p. *Gene* 178;71-74, 1996
18. Clark MA, Hammond FR, Papaioannou A, Hawkins NJ, Ward RL: Regulation and expression of human Fabs under the control of the *Escherichia coli* arabinose promoter. *PBAD*. *Immunotechnol* 3;217-226, 1997
19. Knappik A, Plückthun A: Engineered turns of a recombinant antibody improve its in vivo folding. *Protein Eng* 8;81-89, 1995
20. Deramni AI, Prinz WA, Belin D, Beckwith J: Mutations that allow disulfide bond formation in the cytoplasm of *Escherichia coli*. *Science* 262;1744-1747, 1993
21. He M, Hamon M, Liu H, Kang A, Taussig MJ: Functional expression of a single-chain anti-progesterone antibody fragment in the cytoplasm of a mutant *Escherichia coli*. *Nucleic Acids Res* 23;4009-4010, 1995
22. Jurado P, Ritz D, Beckwith J, deLorenzo V, Fernandez LA: Production of functional single-chain Fv antibodies in the cytoplasm of *Escherichia coli*. *J Mol Biol* 320;1-10, 2002
23. Levy R, Weiss R, Chen G, Iverson BL, Georgiou G:

- Production of correctly folded Fab antibody fragment in the cytoplasm of *Escherichia coli* *txB gor* mutants via the coexpression of molecular chaperones. *Protein Expr Purif* 23; 338-347, 2001
24. Venturi M, Seifert C, Hunte C: High level production of functional antibody Fab fragments in an oxidizing bacterial cytoplasm. *J Mol Biol* 315;1-8, 2002
  25. Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning*. 2nd ed. NY, USA: Cold Spring Harbor Laboratory Press Cold Spring Harbor; 1989
  26. Cha S, Leung PS, Coppel RL, Vandewater J, Ansari AA, Gershwin ME: Heterogeneity of combinatorial human autoantibodies against PDC-E2 and biliary epithelial cells in patients with primary biliary cirrhosis. *Hepatology* 20;574-583, 1994
  27. McCafferty J, Johnson, KS. Construction and screening of antibody display libraries. In: McCafferty J, Johnson KS, editors. *Phage Display of Peptides and Proteins*. A Laboratory Manual. San Diego, CA, USA: Academic Press Inc.; 1996
  28. Brunelle A, Schleif R: Determining residue-base interactions between AraC protein and aral DNA. *J Mol Biol* 209; 607-622, 1989
  29. Menon KP, Lee NL: Activation of ara operons by a truncated AraC protein does not require inducer. *Proc Natl Acad Sci U S A* 87;3708-3712, 1990
  30. Cha S, Leung PS, Gershwin ME, Fletcher MP, Ansari AA, Coppel RL: Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. *Proc Natl Acad Sci U S A* 90;2527-2531, 1993
  31. O'shea EK, Rutkowski R, Stafford WE 3rd, Kim PS: Preferential heterodimer formation by isolated leucine zipper from fos and jun. *Science* 245;646-648, 1989
  32. Griep RA, vanTwisk C, Kerschbaumer RJ, Harper K, Torrance L, Himmler G, vanderWolf JM, Schots A: pSKAP/S: an expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. *Protein Expr Purif* 16;63-69, 1999
  33. Hayhurst A: Improved expression characteristics of single-chain Fv fragments when fused downstream of the *Escherichia coli* maltose-binding protein or upstream of a single immunoglobulin-constant domain. *Protein Expr Purif* 18;1-10, 2000
  34. Bustos SA, Schleif RF: Functional domains of the AraC protein. *Proc Natl Acad Sci U S A* 90;5638-5642, 1993
  35. Strachan G, Williams S, Moyle SP, Harris WJ, Porter AJ: Reduced toxicity of expression, in *Escherichia coli*, of anti pollutant antibody fragments and their use as sensitive diagnostic molecules. *J Appl Microbiol* 87;410-417, 1999
  36. Bessette PH, Aslund F, Beckwith J, Georgiou G: Efficient folding of proteins with multiple disulfide bonds in the *Escherichia coli* cytoplasm. *Proc Natl Acad Sci U S A* 96;13703-13708, 1999